Fierce Pharma
FEBRUARY 22, 2024
As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new owner in the U.S. | As Roche officially abandoned cancer drug Gavreto, its former partner Blueprint Medicines has found the RET inhibitor a new U.S. owner in Rigel Pharmaceuticals.
MedCity News
FEBRUARY 22, 2024
About 80% of all FDA-approved healthcare AI applications are related to radiology — but due to a massive workforce shortage, radiologists don’t have the time to explore, choose, validate and implement the tools available to them. Some providers are using a radiology AI marketplace called CARPL to address this problem, including Massachusetts General Hospital and University Hospitals.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
FEBRUARY 22, 2024
Regeneron and Sanofi have reached another milestone as they look to add to their megablockbuster immunology drug Dupixent a new U.S. | Regeneron and Sanofi have reached another milestone is their advancement of Dupixent (dupilumab) as a potential treatment for uncontrolled chronic obstructive pulmonary disease (COPD) with type 2 inflammation as the FDA has accepted the companies’ application and designated it for priority review with a target action date of June 27.
Copyright Clearance Center
FEBRUARY 22, 2024
February 22, 2024 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, will host the Town Hall event “The Heart of the Matter: Copyright, AI Training and LLMs” via LinkedIn Live on Thursday, 29 February, 11:00 EST/16:00 GMT. A panel of legal experts including Prof. Daniel Gervais , Vanderbilt University Law School, and Prof.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
FEBRUARY 22, 2024
To get a pulse on Moderna following its “year of transition” in 2023, look no further than the company’s manufacturing operations. | To get a pulse on Moderna following its “year of transition” in 2023, look no further than the company’s manufacturing operations. The Cambridge, Massachusetts-based biotech has incurred a COVID-related wind-down charge on one hand, while it spends millions of dollars to bolster cancer vaccines at the same time.
Pharmaceutical Commerce
FEBRUARY 22, 2024
A cohort study investigates how a change in clinical guidelines, an expanded label, and reduction in drug prices can impact the use of PCSK9 inhibitors as a treatment for atherosclerotic cardiovascular disease.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
FEBRUARY 22, 2024
By settling now and agreeing to deferred payments over the next five years, Novavax avoids the risk of being responsible for a much bigger payout all at once. The arbitration hearing over the disputed vaccine purchase agreement with Gavi was scheduled for this summer.
Fierce Pharma
FEBRUARY 22, 2024
Daiichi Sankyo is building additional antibody-drug conjugate capacity at its German site. Astellas partnered with Kelonia on cell therapy tech. | Daiichi Sankyo is investing 1 billion euros to expand its German site. Astellas partnered with Kelonia on cell therapy tech. Novartis launched a strategic review of a subsidiary in India that's focused on older meds.
European Pharmaceutical Review
FEBRUARY 22, 2024
A report by Towards Healthcare has forecasted that the advanced drug delivery market will value $375.86 billion by 2033. The year 2023 was “significant” for the progress of advanced drug delivery systems, the author reflected. Last year, with a size of $234.84 billion, the market witnessed “remarkable advancements that promise to reshape healthcare landscapes across the globe”.
pharmaphorum
FEBRUARY 22, 2024
NICE has backed NHS use of Pfizer’s Litfulo for patients with alopecia areata, the first drug therapy for a condition that affects around 14,000 people
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
European Pharmaceutical Review
FEBRUARY 22, 2024
The National Institute for Health and Care Excellence (NICE) has recommended LITFULO ® (ritlecitinib) for treating certain patients with severe alopecia areata. This is “an important milestone” according to Lynn Clay, Specialty Care Lead at Pfizer UK. The once daily oral capsule is indicated as a treatment option in individuals who are 12 years and older.
MedCity News
FEBRUARY 22, 2024
Without taking specific steps to improve trial diversity, advances in inclusive treatments will continue at a snail’s pace.
pharmaphorum
FEBRUARY 22, 2024
More digital health consolidation as Aptar buys Healint, a specialist in patient support apps and software to run virtual clinical trials and patient registries
MedCity News
FEBRUARY 22, 2024
Now more than ever, enhancing primary care practices to include CGM capabilities is a crucial goal requiring the support and involvement of the broader healthcare community.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
FEBRUARY 22, 2024
The company will evaluate an IMC-F106C/Opdivo combination treatment in a Phase III registrational study called PRISM-MEL-301.
MedCity News
FEBRUARY 22, 2024
Are you a biopharma startup focused on oncology? A devices /diagnostics startup focused on cardiology? Or a health tech startup focused on how consumers/employers are addressing women’s health? If so, submit an application for MedCity INVEST Pitch Perfect by February 29!
Pharmaceutical Technology
FEBRUARY 22, 2024
The FDA has accepted Regeneron’s biologics licence application (BLA) for linvoseltamab to treat multiple myeloma for priority review.
MedCity News
FEBRUARY 22, 2024
Perelel’s $10 million pledge comes in the form of product donations and funding grants and will go to the Magee-Womens Research Institute and the Good+Foundation through 2027.
PharmaTimes
FEBRUARY 22, 2024
The trial is recruiting patients in Leeds, Manchester, Oxford, London, Cambridge and Kent
pharmaphorum
FEBRUARY 22, 2024
Regeneron should hear from the FDA in August on its application for multiple myeloma bispecific linvoseltamab after a priority review.
Clarivate
FEBRUARY 22, 2024
Clients partner with Clarivate consultants for many reasons, including strategic perspective, additional skills, complementary data sets and therapy expertise. In the research and development space, we help companies advance their drug discovery, preclinical proof-of-concept, and regulatory activities. Clarivate’s translational science expertise, regulatory and commercial experts and assets combine to complement client teams in generating long term value.
pharmaphorum
FEBRUARY 22, 2024
FDA warns against use of wearable smartwatches and smart rings that claim to measure blood glucose, which are all unapproved medical devices.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
PharmaTimes
FEBRUARY 22, 2024
Pharmacy First will enable patients to receive treatment for seven common conditions
Rep-Lite
FEBRUARY 22, 2024
Small medical device companies often face unique challenges such as limited resources, intense competition, and a need for precise and compliant communication. Navigating through these challenges can be daunting, but knowing how to build a sales team can be the key to success. But building a high-performing sales team will need a ton of strategy, hard work, and persistence.
Pharmaceutical Commerce
FEBRUARY 22, 2024
Immune-Onc Therapeutics’ IO-202 is currently being analyzed as a monotherapy and in combination for patients with relapsed/refractory acute myeloid leukemia with monocytic differentiation or chronic myelomonocytic leukemia.
PM360
FEBRUARY 22, 2024
Bronze Winner – Verywell Health Verywell Health’s Health Divide: Menopause & Black Women Verywell Health’s Health Divide: Menopause & Black Women sheds light on health inequities experienced by Black women going through menopause by providing information about disparities like increased likelihood and severity of symptoms, reduced access to care, and more.
PharmExec
FEBRUARY 22, 2024
Early-stage trial results indicate that NLRP3 inflammasome inhibitors were able to achieve nearly the same weight loss as Wegovy while also reducing inflammatory biomarkers linked to heart disease.
PM360
FEBRUARY 22, 2024
Deerfield Agency and Beiersdorf Eucerin Sun Product Launch The launch of Eucerin® Sun was a sequential, omnichannel effort made up of three key milestones: reestablishing the clinical standard, introducing a groundbreaking antioxidant complex, and the unveiling of the full product line. Each milestone was pivotal in not only driving recommendations and sales, but also in delivering optimal sun protection for all.
European Pharmaceutical Review
FEBRUARY 22, 2024
In recent months, Pharma and biotech have seen promising developments in line with their efforts to help overcome global antimicrobial resistance (AMR). The discovery and use of antibiotics brought about a groundbreaking transformation in the treatment of bacterial infections, substantially reducing the number of deaths associated with microorganism-related diseases in humans and animals.
PM360
FEBRUARY 22, 2024
Bronze Winner – BrightInsight and CSL Behring The Hizentra App The Hizentra® app was developed to support patients transitioning from in-clinic treatment to at-home self-infusions of Hizentra and to stay compliant. We conducted interviews with patients and physicians to understand the challenges in moving to selfadministered infusions. The app was designed to help patients properly self-infuse and stay compliant by enabling patients to easily track infusions and infusion sites, set reminde
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
269 
Let's personalize your content